Mackenzie Financial’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.11M | Sell |
190,089
-769,778
| -80% | -$41.8M | 0.01% | 707 |
|
|
2026
Q1 | $60.2M | Sell |
959,867
-1,107,981
| -54% | -$88.6M | 0.07% | 225 |
|
|
2025
Q4 | $198M | Sell |
2,067,848
-1,035,660
| -33% | -$102M | 0.23% | 96 |
|
|
2025
Q3 | $303M | Buy |
3,103,508
+1,499,897
| +94% | +$155M | 0.37% | 63 |
|
|
2025
Q2 | $172M | Buy |
1,603,611
+832,272
| +108% | +$84.2M | 0.22% | 105 |
|
|
2025
Q1 | $77.8M | Sell |
771,339
-182,036
| -19% | -$18.3M | 0.11% | 166 |
|
|
2024
Q4 | $85.2M | Buy |
953,375
+249,435
| +35% | +$22M | 0.12% | 157 |
|
|
2024
Q3 | $59M | Buy |
703,940
+36,745
| +6% | +$2.9M | 0.08% | 205 |
|
|
2024
Q2 | $51.4M | Sell |
667,195
-22,207
| -3% | -$1.63M | 0.08% | 211 |
|
|
2024
Q1 | $47.2M | Sell |
689,402
-19,431
| -3% | -$1.25M | 0.07% | 226 |
|
|
2023
Q4 | $41M | Buy |
708,833
+279,513
| +65% | +$14.9M | 0.06% | 235 |
|
|
2023
Q3 | $22.1M | Buy |
429,320
+58,735
| +16% | +$3.08M | 0.04% | 299 |
|
|
2023
Q2 | $19.8M | Sell |
370,585
-50,746
| -12% | -$2.65M | 0.03% | 335 |
|
|
2023
Q1 | $21.1M | Buy |
421,331
+240,903
| +134% | +$11.4M | 0.03% | 328 |
|
|
2022
Q4 | $8.35M | Buy |
180,428
+10,447
| +6% | +$452K | 0.01% | 443 |
|
|
2022
Q3 | $6.58M | Sell |
169,981
-3,613
| -2% | -$145K | 0.01% | 477 |
|
|
2022
Q2 | $6.47M | Buy |
173,594
+63,524
| +58% | +$2.59M | 0.01% | 508 |
|
|
2022
Q1 | $4.88M | Buy |
110,070
+17,558
| +19% | +$761K | 0.01% | 584 |
|
|
2021
Q4 | $3.93M | Sell |
92,512
-4,752
| -5% | -$200K | 0.01% | 628 |
|
|
2021
Q3 | $4.22M | Buy |
97,264
+27,963
| +40% | +$1.24M | 0.01% | 605 |
|
|
2021
Q2 | $2.96M | Sell |
69,301
-21,000
| -23% | -$883K | ﹤0.01% | 652 |
|
|
2021
Q1 | $3.49M | Buy |
90,301
+57,278
| +173% | +$2.17M | 0.01% | 590 |
|
|
2020
Q4 | $1.19M | Sell |
33,023
-47,491
| -59% | -$1.71M | ﹤0.01% | 688 |
|
|
2020
Q3 | $3.08M | Sell |
80,514
-703,991
| -90% | -$27.1M | 0.01% | 480 |
|
|
2020
Q2 | $27.5M | Sell |
784,505
-785,265
| -50% | -$28.3M | 0.07% | 209 |
|
|
2020
Q1 | $51.2M | Sell |
1,569,770
-126,176
| -7% | -$4.93M | 0.16% | 147 |
|
|
2019
Q4 | $76.7M | Sell |
1,695,946
-83,285
| -5% | -$3.48M | 0.19% | 137 |
|
|
2019
Q3 | $72.4M | Buy |
1,779,231
+15,749
| +0.9% | +$667K | 0.19% | 130 |
|
|
2019
Q2 | $75.8M | Buy |
1,763,482
+349,922
| +25% | +$13.5M | 0.2% | 123 |
|
|
2019
Q1 | $54.3M | Buy |
1,413,560
+1,251,310
| +771% | +$47.8M | 0.13% | 166 |
|
|
2018
Q4 | $5.73M | Buy |
162,250
+148,187
| +1,054% | +$5.37M | 0.02% | 476 |
|
|
2018
Q3 | $541K | Buy |
14,063
+1,762
| +14% | +$61.5K | ﹤0.01% | 865 |
|
|
2018
Q2 | $402K | Buy |
12,301
+4,613
| +60% | +$139K | ﹤0.01% | 832 |
|
|
2018
Q1 | $210K | Buy |
+7,688
| New | +$209K | ﹤0.01% | 898 |
|
|
2016
Q2 | – | Sell |
-13,774
| Closed | -$259K | – | 924 |
|
|
2016
Q1 | $259K | Sell |
13,774
-131,105
| -90% | -$2.3M | ﹤0.01% | 744 |
|
|
2015
Q4 | $2.67M | Sell |
144,879
-74,974
| -34% | -$1.34M | 0.02% | 372 |
|
|
2015
Q3 | $3.61M | Buy |
219,853
+34,899
| +19% | +$597K | 0.02% | 321 |
|
|
2015
Q2 | $3.27M | Buy |
184,954
+8,067
| +5% | +$144K | 0.02% | 357 |
|
|
2015
Q1 | $3.14M | Buy |
176,887
+107,087
| +153% | +$1.69M | 0.02% | 366 |
|
|
2014
Q4 | $925K | Buy |
+69,800
| New | +$892K | ﹤0.01% | 553 |
|
|
2013
Q4 | – | Sell |
-68,055
| Closed | -$799K | – | 631 |
|
|
2013
Q3 | $799K | Sell |
68,055
-38,593
| -36% | -$417K | ﹤0.01% | 521 |
|
|
2013
Q2 | $989K | Buy |
+106,648
| New | +$905K | ﹤0.01% | 496 |
|
Other funds holding BSX
Mackenzie Financial's BSX Position: Q2 2026 in Review
Mackenzie Financial reduced its Boston Scientific (BSX) stake by 80% in Q2 2026, selling an estimated $41.8M and leaving 190,089 shares worth $8.11M. The position accounts for 0.01% of the portfolio, ranked #707.
Mackenzie Financial first reported a position in BSX in Q2 2013 and has held it in 42 quarters since. The position peaked at $303M in Q3 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Mackenzie Financial held 190,089 shares of Boston Scientific worth $8.11M as of Q2 2026.
- Mackenzie Financial sold 769,778 Boston Scientific shares in Q2 2026, an estimated $41.8M.
- Boston Scientific made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #707 holding.
- Mackenzie Financial first reported a position in Boston Scientific in Q2 2013 and has held it in 42 quarters since.
- Mackenzie Financial's Boston Scientific position peaked at $303M in Q3 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.